Cemdisiran

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor... (FDA, 2026-11-18)

FDA approves Livsayis (cemdisiran) for gMG. The approval is on record as a sourced regulatory event; the application record has not been loaded yet. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NIMBLE (NCT05070858) · Phase 3 · met primary endpoint · grade pending

Also in development:Age-Related Macular Degeneration · Phase 3Generalized Myasthenia Gravis · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Age-Related Macular Degeneration
Generalized Myasthenia Gravis
Other / comorbidity
NCT07154745 · Regeneron Pharmaceuticals
2026-06-11 – 2031-12-04 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05744921 · Regeneron Pharmaceuticals
2023-03-07 – 2028-10-10 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05131204 · Regeneron Pharmaceuticals
2022-10-06 – 2023-07-12 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Phase 2 (5)
Other / comorbidity
NCT03999840 · Mario Negri Institute for Pharmacological Research
2021-01 – 2024-03 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT04811716 · Regeneron Pharmaceuticals
2021-07-29 – 2023-10-18 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT03841448 · Alnylam Pharmaceuticals
2019-09-30 – 2023-06-27 · IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA
What this study did
NCT04888507 · Regeneron Pharmaceuticals
2021-07-08 – 2023-05-04 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT03303313 · Alnylam Pharmaceuticals
2017-09-19 – 2018-09-12 · Atypical Hemolytic Uremic Syndrome
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02352493 · Alnylam Pharmaceuticals
2015-01 – 2017-08 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
Phase 1 (3)
Other / comorbidity
NCT06479863 · Austin Neuromuscular Center
2024-08-08 – 2027-08-30 · Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
What this study did
NCT04601844 · Regeneron Pharmaceuticals
2020-11-16 – 2021-07-23 · Healthy
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cemdisiran: this drugPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Descartes-08Phase 3Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 3Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cemdisiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Phase 1Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory MyopathiesRecruiting
Est. primary completion 2027-05-30 · NCT06479863 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Phase 3Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-07-31 · NCT06541704 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2028-10-10 · NCT05744921 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2030-01-18 · NCT07154745 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026FDA action dateCemdisiran PDUFA target action date (generalized myasthenia gravis)
US, FDA · FDA · Source ↗

Recent

18 November 2026ApprovalFDA approves Livsayis (cemdisiran) for gMG
US, FDA · Source ↗
22 June 2026Filing acceptedFDA accepts cemdisiran NDA for generalized myasthenia gravis (priority review)
US, FDA · Regeneron Pharmaceuticals · Source ↗
22 June 2026Filing acceptedEMA accepts cemdisiran marketing authorisation application for generalized myasthenia gravis
EU, EMA · Regeneron Pharmaceuticals · Source ↗